BIRKENFELD, GERMANY – STRATEC SE (Frankfurt: SBS; Prime Standard) held its Annual General Meeting today, where shareholders approved all proposed agenda items with clear majorities. The resolutions include a dividend distribution of EUR 0.60 per share for the 2024 financial year, matching the previous year's dividend, and representing a total payout of EUR 7.3 million. The dividend will be paid to shareholders via their depositing banks on June 26, 2026.
In addition to the dividend, shareholders ratified the actions of the Board of Management and the Supervisory Board, approved the remuneration report, and elected PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft (PwC), Frankfurt am Main, as the auditor for the 2026 financial year. The strong shareholder turnout of 70.1% of registered share capital underscores confidence in the company's strategic direction.
This annual meeting highlights STRATEC's commitment to delivering value to its shareholders while maintaining transparent governance. The stable dividend reflects the company's financial performance and its ability to generate consistent returns even in a challenging economic environment. For investors, the approval of all resolutions signals alignment between management and shareholders, which can bolster market confidence.
STRATEC SE, a leading provider of fully automated analyzer systems and consumables for clinical diagnostics and life sciences, continues to strengthen its position in the industry. The company's business model, which covers the entire value chain from development to production and quality assurance, is critical for its partners—who market these systems globally to laboratories, blood banks, and research institutes. The approval of the auditor and remuneration report further reinforces corporate governance standards, which is increasingly important for institutional investors.
The impact of these decisions extends beyond the company. By maintaining a stable dividend, STRATEC supports shareholder income, which can be particularly attractive in a low-yield environment. Moreover, the company's focus on diagnostics and life sciences aligns with global healthcare trends, including the growing demand for automated testing solutions. As the industry evolves, STRATEC's patented technologies and comprehensive service offerings position it to capitalize on market opportunities.
Detailed voting results and further information about the Annual General Meeting are available at www.stratec.com/agm. For additional context, the company's investor relations team can be reached via the contact details on the corporate website.
